Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2011/1793 | Other Identifier | CSET number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Treatment by association of complete surgical excision of the lesions and intraperitoneal immunotherapy using Catumaxomab for patients with gastric peritoneal carcinomatosis
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Schema B (140µg) | Experimental |
|
|
| Schema A (100µg) | Experimental |
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Catumaxomab 100µg | Drug |
| ||
| Catumaxomab 140µg |
| Measure | Description | Time Frame |
|---|---|---|
| Progression Free Survival | every 3 months for the first two years |
| Measure | Description | Time Frame |
|---|---|---|
| Progression Free Survival | every 3 months for the first two years then every 4 months on year 3 then every 6 months on year 4 and 5 |
Not provided
Inclusion Criteria:
Inclusion Criteria (intraoperative):
Exclusion Criteria:
Exclusion Criteria (intraoperative):
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut Gustave Roussy | Villejuif | Val de Marne | 94805 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| ID | Term |
|---|---|
| C522419 | catumaxomab |
Not provided
Not provided
Not provided